Used in targeted cancer immunotherapy, this antibody specifically binds to Claudin-6 (CLDN6), a protein overexpressed in various tumors but largely absent in healthy tissues. Its high specificity makes it valuable for developing antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell therapies. It enables selective delivery of cytotoxic agents to cancer cells, minimizing damage to normal cells. Additionally, it serves as a critical reference tool in preclinical research to evaluate CLDN6 expression, assess therapeutic efficacy, and standardize new anti-CLDN6 candidates. Its role in target validation and assay development supports the advancement of precision oncology treatments.